前列腺特异性膜抗原核素显像及治疗在分化型甲状腺癌中的应用进展

姜玲; 周海中; 姜玲; 周海中

doi:10.3760/cma.j.cn121381-202109013-00205

[1]

Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann OncolAnn Oncol, 2019, 30(12): 1856-1883. doi: 10.1093/annonc/mdz400

[2]

中华医学会核医学分会. ¹³¹I治疗分化型甲状腺癌指南(2021版)[J]. 中华核医学与分子影像杂志, 2021, 41(4): 218-241. doi: 10.3760/cma.j.cn321828-20201113-00412
Chinese Society of Nuclear Medicine. Guidelines for radioiodine therapy of differentiated thyroid cancer (2021 edition)[J]. Chin J Nucl Med Mol ImagingChin J Nucl Med Mol Imaging, 2021, 41(4): 218-241. doi: 10.3760/cma.j.cn321828-20201113-00412

[3]

Kreissl MC, Janssen MJR, Nagarajah J. Current treatment strategies in metastasized differentiated thyroid cancer[J]. J Nucl MedJ Nucl Med, 2019, 60(1): 9-15. doi: 10.2967/jnumed.117.190819

[4]

Berdelou A, Lamartina L, Klain M, et al. Treatment of refractory thyroid cancer[J]. Endocr Relat CancerEndocr Relat Cancer, 2018, 25(4): R209-R223. doi: 10.1530/erc-17-0542

[5]

Schlumberger M, Brose M, Elisei R, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer[J]. Lancet Diabetes EndocrinolLancet Diabetes Endocrinol, 2014, 2(5): 356-358. doi: 10.1016/s2213-8587(13)70215-8

[6]

丛慧, 梁军, 林岩松. 碘难治性分化型甲状腺癌的诊断与靶向治疗[J]. 国际放射医学核医学杂志, 2015, 39(1): 25-31. doi: 10.3760/cma.j.issn.1673-4114.2015.01.007
Cong H, Liang J, Lin YS. Diagnosis and targeted therapy of radioactive iodine-refractory differentiated thyroid cancer[J]. Int J Radiat Med Nucl MedInt J Radiat Med Nucl Med, 2015, 39(1): 25-31. doi: 10.3760/cma.j.issn.1673-4114.2015.01.007

[7]

Schlumberger M, Leboulleux S. Current practice in patients with differentiated thyroid cancer[J]. Nat Rev EndocrinolNat Rev Endocrinol, 2021, 17(3): 176-188. doi: 10.1038/s41574-020-00448-z

[8]

Ito Y, Suzuki S, Ito KI, et al. Tyrosine-kinase inhibitors to treat radioiodine-refracted, metastatic, or recurred and progressive differentiated thyroid carcinoma[J]. Endocr JEndocr J, 2016, 63(7): 597-602. doi: 10.1507/endocrj.EJ16-0064

[9]

赵艳红, 陈跃. ¹⁷⁷Lu-PSMA靶向治疗转移性去势抵抗性前列腺癌的研究进展[J]. 国际放射医学核医学杂志, 2019, 43(4): 373-380. doi: 10.3760/cma.j.issn.1673-4114.2019.04.013
Zhao YH, Chen Y. Progress in radioligand therapy with ¹⁷⁷Lu-PSMA for the treatment of metastatic castration-resistant prostate cancer[J]. Int J Radiat Med Nucl MedInt J Radiat Med Nucl Med, 2019, 43(4): 373-380. doi: 10.3760/cma.j.issn.1673-4114.2019.04.013

[10]

Evans JC, Malhotra M, Cryan JF, et al. The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase Ⅱ (PSMA/GCPII) in cancer and neurological disease[J]. Br J PharmacolBr J Pharmacol, 2016, 173(21): 3041-3079. doi: 10.1111/bph.13576

[11]

Kuten J, Fahoum I, Savin Z, et al. Head-to-head comparison of ⁶⁸Ga-PSMA-11 with ¹⁸F-PSMA-1007 PET/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard[J]. J Nucl MedJ Nucl Med, 2020, 61(4): 527-532. doi: 10.2967/jnumed.119.234187

[12]

Violet J, Jackson P, Ferdinandus J, et al. Dosimetry of ¹⁷⁷Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes[J]. J Nucl MedJ Nucl Med, 2019, 60(4): 517-523. doi: 10.2967/jnumed.118.219352

[13]

Heitkötter B, Steinestel K, Trautmann M, et al. Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid[J/OL]. Oncotarget, 2018, 9(11): 9867−9874[2021-09-25]. https://www.oncotarget.com/article/23984/text. DOI: 10.18632/oncotarget.23984.

[14]

Bychkov A, Vutrapongwatana U, Tepmongkol S, et al. PSMA expression by microvasculature of thyroid tumors-potential implications for PSMA theranostics[J/OL]. Sci Rep, 2017, 7(1): 5202[2021-09-25]. https://www.nature.com/articles/s41598-017-05481-z. DOI: 10.1038/s41598-017-05481-z.

[15]

Moore M, Panjwani S, Mathew R, et al. Well-differentiated thyroid cancer neovasculature expresses prostate-specific membrane antigen— a possible novel therapeutic target[J]. Endocr PatholEndocr Pathol, 2017, 28(4): 339-344. doi: 10.1007/s12022-017-9500-9

[16]

Santhanam P, Russell J, Rooper LM, et al. The prostate-specific membrane antigen (PSMA)-targeted radiotracer ¹⁸F-DCFPyL detects tumor neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer[J]. Med OncolMed Oncol, 2020, 37(11): 98-. doi: 10.1007/s12032-020-01427-0

[17]

Sollini M, di Tommaso L, Kirienko M, et al. PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome[J/OL]. EJNMMI Res, 2019, 9(1): 93[2021-09-25]. https://ejnmmires.springeropen.com/articles/10.1186/s13550-019-0559-9. DOI: 10.1186/s13550-019-0559-9.

[18]

Lengana T, Lawal IO, Mokoala K, et al. ⁶⁸Ga-PSMA: a one-stop shop in radioactive iodine refractory thyroid cancer?[J]. Nucl Med Mol ImagingNucl Med Mol Imaging, 2019, 53(6): 442-445. doi: 10.1007/s13139-019-00621-x

[19]

Lütje S, Gomez B, Cohnen J, et al. Imaging of prostate-specific membrane antigen expression in metastatic differentiated thyroid cancer using ⁶⁸Ga-HBED-CC-PSMA PET/CT[J]. Clin Nucl MedClin Nucl Med, 2017, 42(1): 20-25. doi: 10.1097/rlu.0000000000001454

[20]

de Vries LH, Lodewijk L, Braat AJAT, et al. ⁶⁸Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with ¹⁷⁷Lu-PSMA-617[J/OL]. EJNMMI Res, 2020, 10(1): 18[2021-09-25]. https://ejnmmires.springeropen.com/articles/10.1186/s13550-020-0610-x. DOI: 10.1186/s13550-020-0610-x.

[21]

Sasikumar A, Joy A, Pillai MRA, et al. Rare case of intratracheal metastasis detected on ⁶⁸Ga-prostate-specific membrane antigen PET/CT scan in a case of thyroglobulin elevated negative iodine scan syndrome[J]. Clin Nucl MedClin Nucl Med, 2018, 43(4): 282-283. doi: 10.1097/rlu.0000000000001992

[22]

Verma P, Malhotra G, Agrawal R, et al. Evidence of prostate-specific membrane antigen expression in metastatic differentiated thyroid cancer using ⁶⁸Ga-PSMA-HBED-CC PET/CT[J]. Clin Nucl MedClin Nucl Med, 2018, 43(8): e265-e268. doi: 10.1097/RLU.0000000000002161

[23]

Assadi M, Ahmadzadehfar H. ¹⁷⁷Lu-DOTATATE and ¹⁷⁷Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment[J]. World J Nucl MedWorld J Nucl Med, 2019, 18(4): 406-408. doi: 10.4103/wjnm.WJNM_112_18

[24]

Paschalis A, Sheehan B, Riisnaes R, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer[J]. Eur UrolEur Urol, 2019, 76(4): 469-478. doi: 10.1016/j.eururo.2019.06.030

[25]

Chen W, Lee Z, Awadallah A, et al. Peritumoral/vascular expression of PSMA as a diagnostic marker in hepatic lesions[J/OL]. Diagn Pathol, 2020, 15(1): 92[2021-09-25]. https://diagnosticpathology.biomedcentral.com/articles/10.1186/s13000-020-00982-4. DOI: 10.1186/s13000-020-00982-4.

[26]

Conway RE, Rojas C, Alt J, et al. Prostate-specific membrane antigen (PSMA)-mediated laminin proteolysis generates a pro-angiogenic peptide[J]. AngiogenesisAngiogenesis, 2016, 19(4): 487-500. doi: 10.1007/s10456-016-9521-x

[27]

Li ZF, Di CZ, Li SP, et al. Smart nanotherapeutic targeting of tumor vasculature[J]. Acc Chem ResAcc Chem Res, 2019, 52(9): 2703-2712. doi: 10.1021/acs.accounts.9b00283

[28]

Verburg FA, Krohn T, Heinzel A, et al. First evidence of PSMA expression in differentiated thyroid cancer using [⁶⁸Ga]PSMA-HBED-CC PET/CT[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2015, 42(10): 1622-1623. doi: 10.1007/s00259-015-3065-y

[29]

Taywade SK, Damle NA, Bal C. PSMA expression in papillary thyroid carcinoma: opening a new horizon in management of thyroid cancer?[J]. Clin Nucl MedClin Nucl Med, 2016, 41(5): e263-e265. doi: 10.1097/rlu.0000000000001148

[30]

Kratochwil C, Fendler WP, Eiber M, et al. EANM procedure guidelines for radionuclide therapy with ¹⁷⁷Lu-labelled PSMA-ligands (¹⁷⁷Lu-PSMA-RLT)[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2019, 46(12): 2536-2544. doi: 10.1007/s00259-019-04485-3

[31]

Lawhn-Heath C, Yom SS, Liu CY, et al. Gallium-68 prostate-specific membrane antigen ([⁶⁸Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study[J/OL]. EJNMMI Res, 2020, 10(1): 128[2021-09-25]. https://ejnmmires.springeropen.com/articles/10.1186/s13550-020-00720-3. DOI: 10.1186/s13550-020-00720-3.

[32]

Kim YJ, Kim YI. Therapeutic responses and survival effects of ¹⁷⁷Lu-PSMA-617 radioligand therapy in metastatic castrate-resistant prostate cancer: a meta-analysis[J]. Clin Nucl MedClin Nucl Med, 2018, 43(10): 728-734. doi: 10.1097/rlu.0000000000002210

[33]

Jansen BHE, Kramer GM, Cysouw MCF, et al. Healthy tissue uptake of ⁶⁸Ga-prostate-specific membrane antigen, ¹⁸F-DCFPyL, ¹⁸F-fluoromethylcholine, and ¹⁸F-dihydrotestosterone[J]. J Nucl MedJ Nucl Med, 2019, 60(8): 1111-1117. doi: 10.2967/jnumed.118.222505